234 related articles for article (PubMed ID: 28986119)
1. Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions.
Otani IM; Lax T; Long AA; Slawski BR; Camargo CA; Banerji A
J Allergy Clin Immunol Pract; 2018; 6(4):1266-1273.e2. PubMed ID: 28986119
[TBL] [Abstract][Full Text] [Related]
2. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
[TBL] [Abstract][Full Text] [Related]
3. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
Picard M; Pur L; Caiado J; Giavina-Bianchi P; Galvão VR; Berlin ST; Campos SM; Matulonis UA; Castells MC
J Allergy Clin Immunol; 2016 Apr; 137(4):1154-1164.e12. PubMed ID: 26725998
[TBL] [Abstract][Full Text] [Related]
5. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
Picard M; Castells MC
Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
[TBL] [Abstract][Full Text] [Related]
6. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
8. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
9. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
10. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
[TBL] [Abstract][Full Text] [Related]
11. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
[TBL] [Abstract][Full Text] [Related]
12. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
15. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
16. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
17. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
Haine AI; Notenboom CMAW; Tan LVP; Ruiter R; van der Deure WM
Pharmacol Res Perspect; 2022 Aug; 10(4):e00985. PubMed ID: 35811355
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Bernstein BJ
Ann Pharmacother; 2000 Nov; 34(11):1332-5. PubMed ID: 11098349
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity Reactions to Taxanes: A Multicenter Study for Outcomes and Safety of Rapid Drug Desensitization.
Bayrak Durmaz MS; Unutmaz DG; Demir M; Goksel O; Dursun AB; Bavbek S
Allergy Asthma Immunol Res; 2024 Mar; 16(2):142-153. PubMed ID: 38528382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]